{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:05:08Z","timestamp":1794542708551,"version":"4.9.1"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.rmed.2025.107957","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T19:58:47Z","timestamp":1737489527000},"page":"107957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Challenges in treating patients with comorbid asthma and bronchiectasis"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Patella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.rmed.2025.107957_bib1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/02770903.2020.1784194","article-title":"How does comorbid bronchiectasis affect asthmatic patients? A meta-analysis","volume":"58","author":"Lan","year":"2021","journal-title":"J. Asthma"},{"issue":"7","key":"10.1016\/j.rmed.2025.107957_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2025.107957_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.rmed.2018.10.031","article-title":"A comprehensive approach to lung function in bronchiectasis","volume":"145","author":"Radovanovic","year":"2018","journal-title":"Respir. Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.107957_bib5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-2600(24)00176-0","article-title":"Rethinking bronchiectasis as an inflammatory disease","volume":"12","author":"Long","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.107957_bib6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.164.9.2105083","article-title":"Bronchial inflammation and colonization in patients with clinically stable bronchiectasis","volume":"164","author":"Angrill","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.rmed.2025.107957_bib7","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity Is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.rmed.2025.107957_bib8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterization of eosinophilic bronchiectasis: a European multicohort study","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.107957_bib9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaip.2022.10.027","article-title":"Significance and potential role of eosinophils in non-cystic fibrosis bronchiectasis","volume":"11","author":"Guan","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-023-00668-w","article-title":"Elevated eosinophil counts in acute exacerbations of bronchiectasis: unveiling a distinct clinical phenotype","volume":"202","author":"Chen","year":"2024","journal-title":"Lung"},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1159\/000507228","article-title":"The link between asthma and bronchiectasis: state of the art","volume":"99","author":"Crimi","year":"2020","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2025.107957_bib12","first-page":"178","article-title":"Is bronchiectasis (BE) properly Investigated in patients with severe asthma? A real-life report from eight Italian centers","volume":"3","author":"Carpagnano","year":"2023","journal-title":"JCT Res."},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaci.2024.01.027","article-title":"Bronchiectasis and asthma: data from the European bronchiectasis registry (EMBARC)","volume":"153","author":"Polverino","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/ACI.0000000000000492","article-title":"Bronchiectasis and asthma: a dangerous liaison?","volume":"19","author":"Crimi","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaip.2022.09.008","article-title":"Clinical associations of mucus plugging in moderate to severe asthma","volume":"11","author":"Chan","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.anai.2022.11.024","article-title":"Clinical characteristics of the asthma bronchiectasis phenotype","volume":"130","author":"Chan","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2025.107957_bib18","article-title":"Clinical features of asthma with comorbid bronchiectasis: a systematic review and meta-analysis","volume":"100","author":"Zhang","year":"2021","journal-title":"Medicine (Baltim.)"},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention Program coordinating committee expert panel working group","volume":"146","author":"Mm","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2018-000348","article-title":"British Thoracic Society guideline for bronchiectasis in adults","volume":"5","author":"Hill","year":"2018","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbres.2017.07.016","article-title":"Spanish guidelines on treatment of bronchiectasis in adults","volume":"54","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Arch. Bronconeumol."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5694\/mjac14.00287","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines","volume":"202","author":"Chang","year":"2015","journal-title":"Med. J. Aust."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/atm.ATM_171_17","article-title":"The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis","volume":"12","author":"Al-Jahdali","year":"2017","journal-title":"Ann. Thorac. Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.107957_bib25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1055\/a-2311-9450","article-title":"Management erwachsener Patientinnen und Patienten mit Bronchiektasen-Erkrankung","volume":"78","author":"Ringshausen","year":"2024","journal-title":"Pneumologie"},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00700-2023","article-title":"Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?","volume":"62","author":"Cazzola","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12931-018-0770-7","article-title":"Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways","volume":"19","author":"Calzetta","year":"2018","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib28","article-title":"Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma","volume":"3","author":"Chauhan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1164\/rccm.202011-4236ED","article-title":"National asthma education and prevention Program 2020 guideline update: where do we go from here?","volume":"203","author":"Krishnan","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European respiratory society\/American thoracic society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"24","key":"10.1016\/j.rmed.2025.107957_bib31","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2021.7872","article-title":"Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis","volume":"325","author":"Kim","year":"2021","journal-title":"JAMA"},{"issue":"38","key":"10.1016\/j.rmed.2025.107957_bib32","article-title":"The efficacy and safety of long-term add-on treatment of azithromycin in asthma: a systematic review and meta-analysis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltim.)"},{"issue":"12","key":"10.1016\/j.rmed.2025.107957_bib33","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3390\/ijms18122666","article-title":"Azithromycin and chloramphenicol diminish neutrophil extracellular traps (NETs) release","volume":"18","author":"Bystrzycka","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.rmed.2025.107957_bib34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2025.107957_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1331000","article-title":"Neutrophil extracellular traps and their implications in airway inflammatory diseases","volume":"10","author":"Xuan","year":"2024","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0954-6111(06)80227-1","article-title":"Inhaled steroids in patients with bronchiectasis","volume":"86","author":"Elborn","year":"1992","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1164\/ajrccm.158.3.9710090","article-title":"Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis","volume":"158","author":"Tsang","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.107957_bib38","first-page":"1301","article-title":"Exhaled nitric oxide in bronchiectasis: the effects of inhaled corticosteroid therapy","volume":"8","author":"Tsang","year":"2004","journal-title":"Int. J. Tubercul. Lung Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/thx.2002.003236","article-title":"Inhaled fluticasone in bronchiectasis: a 12 month study","volume":"60","author":"Tsang","year":"2005","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.rmed.2025.107957_bib40","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.rmed.2005.12.002","article-title":"Inhaled steroids improve quality of life in patients with steady-state bronchiectasis","volume":"100","author":"Mart\u00ednez-Garc\u00eda","year":"2006","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.107957_bib41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s11096-012-9659-6","article-title":"Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis","volume":"34","author":"Hernando","year":"2012","journal-title":"Int. J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.rmed.2025.107957_bib42","article-title":"Inhaled corticosteroids for bronchiectasis","volume":"5","author":"Kapur","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib43","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00069007","article-title":"Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms","volume":"31","author":"Fuschillo","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.rmed.2025.107957_bib44","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.rmed.2025.107957_bib45","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/thoraxjnl-2013-203773","article-title":"The yin and the yang of immunosuppression with inhaled corticosteroids","volume":"68","author":"Sabroe","year":"2013","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.rmed.2025.107957_bib46","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/biomedicines9101312","article-title":"Inhaled corticosteroids and the lung microbiome in COPD","volume":"9","author":"Keir","year":"2021","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.rmed.2025.107957_bib47","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1164\/rccm.202109-2024ED","article-title":"Balancing benefits and risks: do inhaled corticosteroids modify the lung microbiome?","volume":"204","author":"Singh","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thorax.57.1.15","article-title":"Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors","volume":"57","author":"Angrill","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2025.107957_bib49","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2147\/COPD.S311236","article-title":"Inhaled corticosteroid therapy in bronchiectasis is associated with all-cause mortality: a prospective cohort study","volume":"16","author":"H\u00e5kansson","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"14","key":"10.1016\/j.rmed.2025.107957_bib50","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s40265-022-01785-1","article-title":"Inhaled corticosteroids in adults with non-cystic fibrosis bronchiectasis: from bench to bedside. A narrative review","volume":"82","author":"Mart\u00ednez-Garc\u00eda","year":"2022","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib51","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00453-2020","article-title":"Blood eosinophils predict inhaled fluticasone response in bronchiectasis","volume":"56","author":"Aliberti","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib52","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.chest.2023.04.029","article-title":"The U-Shaped relationship between eosinophil count and bronchiectasis severity: the effect of inhaled corticosteroids","volume":"164","author":"Mart\u00ednez-Garc\u00eda","year":"2023","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.rmed.2025.107957_bib53","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/all.14766","article-title":"Long-acting muscarinic antagonists and small airways in asthma: which link?","volume":"76","author":"Cazzola","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12931-016-0386-8","article-title":"Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells","volume":"17","author":"Cazzola","year":"2016","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.107957_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pupt.2019.03.004","article-title":"Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways","volume":"56","author":"Calzetta","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3 Pt 1","key":"10.1016\/j.rmed.2025.107957_bib56","first-page":"L263","article-title":"Increased acetylcholine release in tracheas from allergen-exposed IgE-immune mice","volume":"266","author":"Larsen","year":"1994","journal-title":"Am. J. Physiol."},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1034\/j.1399-3003.1999.14b13.x","article-title":"Passive sensitization of human airways increases responsiveness to leukotriene C4","volume":"14","author":"Schmidt","year":"1999","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12931-024-02710-8","article-title":"The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro","volume":"25","author":"Matera","year":"2024","journal-title":"Respir. Res."},{"issue":"11","key":"10.1016\/j.rmed.2025.107957_bib59","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-023-01897-2","article-title":"Might it be appropriate to anticipate the use of long-acting muscarinic antagonists in asthma?","volume":"83","author":"Cazzola","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-021-01646-3","article-title":"Rationale and clinical use of bronchodilators in adults with bronchiectasis","volume":"82","author":"Mart\u00ednez-Garc\u00eda","year":"2022","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib61","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02184-2021","article-title":"Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial","volume":"59","author":"Jayaram","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib63","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.21037\/jtd.2018.02.13","article-title":"Aberrant epithelial remodeling with impairment of cilia architecture in non-cystic fibrosis bronchiectasis","volume":"10","author":"Chen","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"Suppl. 63","key":"10.1016\/j.rmed.2025.107957_bib64","article-title":"Airway hyperresponsiveness in bronchiectasis [abstract]","volume":"54","author":"de Koning Gans","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"suppl 68","key":"10.1016\/j.rmed.2025.107957_bib65","article-title":"Use of bronchodilators in bronchiectasis: data from EMBARC [abstract]","volume":"64","author":"Nigro","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib66","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/thoraxjnl-2021-217160","article-title":"Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease","volume":"77","author":"Ekl\u00f6f","year":"2022","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.rmed.2025.107957_bib67","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.3390\/jcm11123539","article-title":"Use of inhaled corticosteroids and risk of acquiring Haemophilus influenzae in patients with chronic obstructive pulmonary disease","volume":"11","author":"Mohsin","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.rmed.2025.107957_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.108960","article-title":"The safety of long-term use of inhaled corticosteroids in patients with asthma: a systematic review and meta-analysis","volume":"236","author":"Shang","year":"2022","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib69","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01896-2018","article-title":"Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis","volume":"54","author":"Henkle","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2025.107957_bib70","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1080\/02770903.2023.2203743","article-title":"Does asthma-bronchiectasis overlap syndrome (ABOS) really exist?","volume":"60","author":"Tiotiu","year":"2023","journal-title":"J. Asthma"},{"key":"10.1016\/j.rmed.2025.107957_bib71","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2147\/COPD.S143656","article-title":"Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD","volume":"12","author":"Janson","year":"2017","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.107957_bib72","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.2147\/COPD.S269637","article-title":"Intraclass difference in pneumonia risk with fluticasone and budesonide in COPD: a systematic review of evidence from direct-comparison studies","volume":"15","author":"Lodise","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1465-9921-10-104","article-title":"The bioavailability and airway clearance of the steroid component of budesonide\/formoterol and salmeterol\/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial","volume":"10","author":"Dalby","year":"2009","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib74","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00518-2024","article-title":"Bronchiectasis management in adults: state of the art and future directions","volume":"63","author":"Choi","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"16","key":"10.1016\/j.rmed.2025.107957_bib75","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.3390\/jcm11164702","article-title":"Can leukotriene receptor antagonist therapy improve the control of patients with severe asthma on biological therapy and coexisting bronchiectasis? A pilot study","volume":"11","author":"Quaranta","year":"2022","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.107957_bib76","article-title":"Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis","volume":"2000","author":"Corless","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib77","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1378\/chest.11-0180","article-title":"Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis","volume":"141","author":"Mart\u00ednez-Garc\u00eda","year":"2012","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.rmed.2025.107957_bib78","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.rmed.2015.08.005","article-title":"Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside","volume":"109","author":"Cazzola","year":"2015","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/15412555.2014.922172","article-title":"Translational study searching for synergy between glycopyrronium and indacaterol","volume":"12","author":"Cazzola","year":"2015","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.21037\/jtd-20-1282","article-title":"Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study","volume":"13","author":"Lee","year":"2021","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib81","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/pr.119.018150","article-title":"Pharmacology and therapeutics of bronchodilators revisited","volume":"72","author":"Matera","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.rmed.2025.107957_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105801","article-title":"Indacaterol, glycopyrronium, and mometasone: pharmacological interaction and anti-inflammatory profile in hyperresponsive airways","volume":"172","author":"Rogliani","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.rmed.2025.107957_bib83","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.arbres.2023.07.013","article-title":"Dual broncodilator and triple therapy in bronchiectasis. clinical trials are urgently needed","volume":"59","author":"Cazzola","year":"2023","journal-title":"Arch. Bronconeumol."},{"issue":"8","key":"10.1016\/j.rmed.2025.107957_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-071906","article-title":"Dual bronchodilators in bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis","volume":"13","author":"Morton","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmed.2025.107957_bib85","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2147\/COPD.S419056","article-title":"Novel anti-inflammatory approaches to COPD","volume":"18","author":"Cazzola","year":"2023","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/17476348.2018.1457437","article-title":"Innovations in asthma therapy: is there a role for inhaled statins?","volume":"12","author":"Zeki","year":"2018","journal-title":"Expet Rev. Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.107957_bib87","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.jaip.2021.04.014","article-title":"Association between statin medication and asthma\/asthma exacerbation in a national health screening cohort","volume":"9","author":"Kim","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib88","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaip.2023.10.029","article-title":"Real-world effectiveness of statin therapy in adult asthma","volume":"12","author":"Park","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"4","key":"10.1016\/j.rmed.2025.107957_bib89","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/02770903.2021.1879850","article-title":"The effect of statins for asthma. A systematic review and meta-analysis","volume":"59","author":"Sunata","year":"2022","journal-title":"J. Asthma"},{"issue":"22","key":"10.1016\/j.rmed.2025.107957_bib90","first-page":"8401","article-title":"Statins improve asthma symptoms by suppressing inflammation: a meta-analysis based on RCTs","volume":"26","author":"Zhang","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib91","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-2600(14)70050-5","article-title":"Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial","volume":"2","author":"Mandal","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.107957_bib92","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chest.2017.05.017","article-title":"A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with Pseudomonas aeruginosa: a proof of concept study","volume":"152","author":"Bedi","year":"2017","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib93","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000368800","article-title":"Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease","volume":"165","author":"Page","year":"2014","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.rmed.2025.107957_bib94","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/JEP.S242961","article-title":"New avenues for phosphodiesterase inhibitors in asthma","volume":"13","author":"Matera","year":"2021","journal-title":"J. Exp. Pharmacol."},{"issue":"7","key":"10.1016\/j.rmed.2025.107957_bib95","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17460441.2016.1184642","article-title":"The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"11","author":"Cazzola","year":"2016","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.rmed.2025.107957_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.518345","article-title":"Phosphodiesterase-4 inhibitors for non-COPD respiratory diseases","volume":"12","author":"Kawamatawong","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4046\/trd.2021.0051","article-title":"Efficacy of roflumilast in bronchiectasis patients with frequent exacerbations: a double-blinded, randomized, placebo-controlled pilot clinical trial","volume":"85","author":"Juthong","year":"2022","journal-title":"Tuberc. Respir. Dis."},{"key":"10.1016\/j.rmed.2025.107957_bib98","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.apha.2023.05.001","article-title":"Phosphodiesterase inhibitors and lung diseases","volume":"98","author":"Stolfa","year":"2023","journal-title":"Adv. Pharmacol."},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4155\/ppa-2018-0030","article-title":"Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3\/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease","volume":"7","author":"Cazzola","year":"2018","journal-title":"Pharm Pat Anal"},{"key":"10.1016\/j.rmed.2025.107957_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101814","article-title":"Efficacy and safety of a first-in-class inhaled PDE3\/4 inhibitor (ensifentrine) vs salbutamol in asthma","volume":"58","author":"Bjermer","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2025.107957_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107826","article-title":"Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis","volume":"224","author":"Turner","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.rmed.2025.107957_bib102","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1016\/j.jaip.2021.08.014","article-title":"Super-responders to severe asthma treatments: defining a new paradigm","volume":"9","author":"Rupani","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib103","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01333-2019","article-title":"Anti-IL5 and anti-IL5R\u03b1 therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series","volume":"55","author":"Rademacher","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.107957_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106491","article-title":"Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study","volume":"185","author":"Crimi","year":"2021","journal-title":"Respir. Med."},{"issue":"12","key":"10.1016\/j.rmed.2025.107957_bib105","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.3390\/jcm12123953","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with co-presence of bronchiectasis: a real-world multicentre observational study","volume":"12","author":"Campisi","year":"2023","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.107957_bib106","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/j.jaip.2023.05.041","article-title":"Real-world effectiveness of IL-5\/5Ra targeted biologics in severe eosinophilic asthma with comorbid bronchiectasis","volume":"11","author":"Bendien","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107957_bib107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S196200","article-title":"Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab","volume":"12","author":"Carpagnano","year":"2019","journal-title":"J. Asthma Allergy"},{"issue":"9","key":"10.1016\/j.rmed.2025.107957_bib108","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/17460441.2023.2230885","article-title":"An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma","volume":"18","author":"Matera","year":"2023","journal-title":"Expet Opin. Drug Discov."},{"issue":"19","key":"10.1016\/j.rmed.2025.107957_bib109","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.107957_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1147","article-title":"Tezepelumab treatment for allergic bronchopulmonary aspergillosis","volume":"11","author":"Ogata","year":"2023","journal-title":"Respirol Case Rep"},{"issue":"6","key":"10.1016\/j.rmed.2025.107957_bib111","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jaci.2019.08.039","article-title":"IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation","volume":"144","author":"Allinne","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib112","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02210-2022","article-title":"Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE\/EGFR signalling complex","volume":"62","author":"Strickson","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2025.107957_bib113","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.mucimm.2023.07.002","article-title":"IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma","volume":"16","author":"Curren","year":"2023","journal-title":"Mucosal Immunol."},{"issue":"18","key":"10.1016\/j.rmed.2025.107957_bib114","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.107957_bib115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.107957_bib116","first-page":"359","article-title":"Brensocatib","volume":"46","author":"Cazzola","year":"2021","journal-title":"Drugs Future"},{"key":"10.1016\/j.rmed.2025.107957_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1239151","article-title":"Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease","volume":"14","author":"Chalmers","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2025.107957_bib118","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","journal-title":"Respir. Res."},{"issue":"Suppl 4","key":"10.1016\/j.rmed.2025.107957_bib119","first-page":"A290","article-title":"Dipeptidyl peptidase-1 inhibition in bronchiectasis with eosinophilic endotype in the WILLOW trial [abstract]","volume":"78","author":"Chalmers","year":"2023","journal-title":"Thorax"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:30:13Z","timestamp":1774427413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":118,"alternative-id":["S0954611125000198"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.107957","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in treating patients with comorbid asthma and bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.107957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107957"}}